- Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
- CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
- CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
- CEL-SCI Appoints Mario Gobbo to Its Board of Directors
- CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
More ▼
Key statistics
On Monday, CEL-SCI Corp (LSRM:MUN) closed at 1.19, 16.76% above the 52 week low of 1.02 set on Oct 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.19 |
---|---|
High | 1.19 |
Low | 1.19 |
Bid | 1.18 |
Offer | 1.22 |
Previous close | 1.18 |
Average volume | 428.57 |
---|---|
Shares outstanding | 54.16m |
Free float | 52.38m |
P/E (TTM) | -- |
Market cap | 69.32m USD |
EPS (TTM) | -0.6304 USD |
Data delayed at least 15 minutes, as of Jun 10 2024 07:15 BST.
More ▼